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Human immunodeficiency virus type 1 protease inhibitors (HIVPIs) and pepstatin are aspartic protease
inhibitors with antimalarial activity. In contrast to pepstatin, HIVPIs were not synergistic with a cysteine
protease inhibitor or more active against parasites with the cysteine protease falcipain-2 knocked out than
against wild-type parasites. As with pepstatin, HIVPIs were equally active against wild-type parasites and
against parasites with the food vacuole plasmepsin aspartic proteases knocked out. The antimalarial mechanism of HIVPIs differs from that of pepstatin.
falciparum (W2 strain) parasites were cultured in RPMI medium supplemented with 10% serum and synchronized with
5% D-sorbitol as previously described (11). Ring stage parasites were incubated with study drugs (0.039 to 10 M, from
stock solutions concentrated 1,000-fold in dimethyl sulfoxide
[DMSO]) or with equivalent concentrations of DMSO for 48 h,
fixed with 1% formaldehyde in phosphate-buffered saline for
48 h, and labeled with 1 nM YOYO-1 dye (Molecular Probes) in
0.1% Triton X-100 in phosphate-buffered saline. Parasitemias
were determined from dot plots acquired with a FACSort flow
cytometer, and 50% inhibitory concentration (IC50) values were
calculated as previously described (11, 12). Potential synergy was
evaluated as the sum of the fractional inhibitory concentrations
(sum FIC) by the following equation: sum FIC ⫽ [(IC50 drug
A in combination)/(IC50 drug A alone)] ⫹ [(IC50 drug B in
combination)/(IC50 drug B alone)]. The sum FIC value for
lopinavir and E-64 was 2.04 ⫾ 0.48 (mean ⫾ standard deviation of results from two experiments, each done in triplicate).
Thus, lopinavir and E-64 (Sigma-Aldrich) showed no evidence
of synergism, but rather borderline antagonism. In contrast,
E-64 and pepstatin have shown marked synergy with a sum FIC
value of 0.54 ⫾ 0.16 (10).
To further characterize the antimalarial mechanism of
HIVPIs, we tested the compounds against P. falciparum parasites with disrupted food vacuole proteases. For plasmepsin
knockout parasites, previously described 3D7 strain parasites
were used (5). For falcipain-2 knockout parasites, procedures
very similar to those previously described were used (11).
Briefly, 3D7 strain parasites were transfected with the pHTK⌬FP2 plasmid, selected with WR99210 until integration of the
plasmids was detected, enriched for recombinant parasites
through negative selection with ganciclovir, and cloned to obtain pure recombinant parasites. Wild-type 3D7 and plasmepsin knockout parasites were incubated in microwell cultures in
the presence of serial dilutions of lopinavir, ritonavir, and
saquinavir (0.025 to 150 M, from 1,000-fold-concentrated

Human immunodeficiency virus type 1 (HIV-1) and malaria
are coendemic throughout much of the developing world.
HIV-1 expresses an aspartic protease, which is an important
drug target (3). In addition to their important antiretroviral
activity, HIV-1 protease inhibitors (HIVPIs) are active against
Plasmodium falciparum in vitro and against rodent malaria
parasites in murine models (7, 9, 13). The predicted targets of
these inhibitors are plasmepsins, a family of aspartic proteases
of malaria parasites. A number of plasmepsins act in concert
with falcipain cysteine proteases and other enzymes to hydrolyze hemoglobin in the P. falciparum food vacuole (5, 8). Several HIVPIs inhibit the food vacuole protease plasmepsin II
(7) and a homologous protease of the rodent parasite Plasmodium chabaudi (6). Pepstatin, the most-studied aspartic protease inhibitor, also exhibits activity against cultured malaria
parasites and inhibits several plasmepsins (2, 6). As the antimalarial activity of HIVPIs may have important implications in
areas where those treated for HIV-1 infection are at risk of
malaria, and as both HIVPIs and pepstatin may serve as leads
for new antimalarial agents, it was of interest to compare their
antimalarial mechanisms of action.
Insight into the antimalarial mechanisms of protease inhibitors came from studies that showed that cysteine protease inhibitors [N-(trans-epoxysuccinyl)-L-leucine-4-guanidinobutylamide (E-64)] and aspartic protease inhibitors (pepstatin)
display marked synergy against malaria parasites (1, 10). Further
supporting an important interaction between these two classes of
proteases, pepstatin had markedly enhanced activity against P.
falciparum parasites in which the gene for the cysteine protease
falcipain-2 was disrupted (11). It was of interest to determine
if HIVPIs had effects similar to those of pepstatin.
We evaluated the HIVPI lopinavir for synergy with E-64. P.
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TABLE 1. Activity of HIV-1 protease inhibitors against
P. falciparum plasmepsin knockout parasites
IC50 (M) for P. falciparuma

Drug
Saquinavir
Ritonavir
Lopinavir

TABLE 2. Activity of HIV-1 protease inhibitors against
P. falciparum falcipain-2 knockout parasites
IC50 (M) for P. falciparuma

Wild type

PMPI KO

PMPII KO

HAP KO

PMPI/IV KO

12.2 ⫾ 0.3
12.2 ⫾ 0.4
3.0 ⫾ 0.4

11.6 ⫾ 0.6
11.4 ⫾ 1.0
2.4 ⫾ 0.2

11.1 ⫾ 0.3
11.7 ⫾ 0.4
2.5 ⫾ 0.1

15.1 ⫾ 2.7
14.5 ⫾ 0.5
3.2 ⫾ 0.2

13.4 ⫾ 0.7
12.4 ⫾ 0.6
3.9 ⫾ 0.7

stocks in DMSO) or with equivalent concentrations of DMSO
for 44 h, beginning at the ring stage, and then 0.5 Ci of
[3H]hypoxanthine (178.7 Ci/mmol; Perkin Elmer) was added.
The incubation was continued for 16 h, the parasites were
harvested, the hypoxanthine uptake rates of treated and control parasites were compared, and IC50 values were generated
as previously described (5). The antimalarial activities of seven
HIVPIs against 3D7 wild-type and falcipain-2 knockout parasites were evaluated by assessing the fluorescence of YOYO1-stained parasites and determining IC50 values using fluorescence-activated cell sorter-based analysis as described above
(11, 12).
HIVPIs had similar activities against control, plasmepsin
knockout (Table 1), and falcipain-2 knockout (Table 2) parasites. Discrepancies between reported IC50 values in Tables 1
and 2 likely reflect differences between the [3H]hypoxanthine
uptake and fluorescence-activated cell sorter-based assay
methods. Considering the actions of other protease inhibitors,
E-64 was about twice as active against falcipain-2 knockout and
plasmepsin knockout parasites as it was against control parasites, as previously described (5). Pepstatin (Sigma-Aldrich)
was about equally active against control and plasmepsin knockout parasites but was much more active against falcipain-2
knockout parasites, all consistent with prior findings (5, 11).
Our results identify major differences between the antimalarial activities of pepstatin and HIVPIs. Pepstatin, the most
widely available broadly active aspartic protease inhibitor (3),
inhibits multiple plasmepsins and rapidly kills cultured parasites, but its antimalarial mechanism of action is uncertain. For
both pepstatin and HIVPIs, activities were similar against wildtype and plasmepsin knockout parasites. These results suggest
the functional redundancy of plasmepsins but do not shed light
on the mechanism of HIVPIs. In contrast, the activities of
pepstatin and HIVPIs differed markedly when evaluated for
antimalarial synergy with the cysteine protease inhibitor E-64
or for activity against falcipain-2 knockout parasites. Pepstatin
shows strong synergy with cysteine protease inhibitors (10),
and it is remarkably more potent against falcipain-2 knockout
parasites than against wild-type parasites (11). These results
suggest important biological interactions between falcipains
and plasmepsins. Surprisingly, the HIVPIs were not synergistic
with E-64 and were not more active against falcipain-2 knockout parasites than against wild-type parasites. Thus, although
we cannot yet identify specific biological targets for either
pepstatin or HIVPIs in malaria parasites, our results strongly
suggest that the compounds act differently.
P. falciparum encodes 10 predicted aspartic protease genes
(14). In addition to the four food vacuole plasmepsins (I to

Saquinavir
Ritonavir
Indinavir
Nelfinavir
Amprenavir
Lopinavir
Atazanavir
Pepstatin
E-64
a

Wild type

Falcipain-2
knockout

5.7 ⫾ 0.8
7.9 ⫾ 1.1
25.2 ⫾ 4.4
21.8 ⫾ 2.4
71.24 ⫾ 16.1
2.5 ⫾ 0.4
35.0 ⫾ 7.4
7.5 ⫾ 0.4
2.4 ⫾ 0.4

7.6 ⫾ 1.7
8.9 ⫾ 0.9
26.6
24.7
84.7
3.4 ⫾ 0.8
42.0
0.04 ⫾ 0.01
1.4 ⫾ 0.1

Knockout IC50
(% of wild-type IC50)
133
113
105
113
118
138
120
0.5
58

IC50 data are means ⫾ standard deviations of results from three experiments.

IV), another quite different aspartic protease, plasmepsin V,
was recently characterized (4). This protease is not located in
the food vacuole and does not bind pepstatin. The HIV-1
protease is also quite different from the food vacuole plasmepsins (15). These structural differences may offer insight
into the differential effects of the HIVPIs and pepstatin. Previously we showed that HIVPIs inhibit recombinant plasmepsin II (7), but the intracellular target of these inhibitors is
unknown. Thus, pepstatin may target food vacuole plasmepsins, which are dependent on food vacuole cysteine proteases for maximal activity, while HIVPIs may target other
aspartic proteases, such as plasmepsin V. In addition to differential inhibition of parasite proteases, various effects may be
due to differential access to the food vacuole or other cellular
compartments. Alternatively, either pepstatin or HIVPIs might
exert antimalarial effects that are unrelated to protease inhibition. Our results do not yet identify a specific mechanism of
action for HIVPIs, but they offer the surprising finding that
HIVPIs do not, as would have been predicted, act in the same
manner as pepstatin. Further research into the precise mode of
action of HIVPIs and other antimalarial aspartic protease inhibitors is warranted to provide insight into the development of
protease inhibitors as new antimalarial drugs and to understand the means by which antiretroviral drugs may offer protection against malaria.
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